Say what? Com­pas­sion­ate use pro­gram? What com­pas­sion­ate use pro­gram?

It’s no se­cret that the av­er­age biotech com­pa­ny is no great fan of com­pas­sion­ate use re­quests for their ex­per­i­men­tal drugs. They can be ex­pen­sive to sat­is­fy and present a po­ten­tial threat if the drug back­fires with an un­ex­pect­ed side ef­fect.

So it’s no great sur­prise that the typ­i­cal biotech com­pa­ny doesn’t pro­vide a sim­ple on­line gate­way for pa­tients des­per­ate to gain ac­cess to their ex­per­i­men­tal ther­a­pies out­side of tri­als. And if the 21st Cen­tu­ry Cures Act ever pass­es, that could present an is­sue in need of quick res­o­lu­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.